Showing results (11-20 of 73) with videos related to
Sort By:
Pageof 8
Plos One|December 21, 2017
aCNViewer: Comprehensive genome-wide visualization of absolute copy number and copy neutral variationsVictor Renault, Jörg Tost, Fabien Pichon, et al.Genes, Chromosomes & Cancer|July 11, 2017
Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle studyVirginie Bubien, Françoise Bonnet, Jennifer Dupiot-Chiron, et al.Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 29, 2014
High-resolution analysis of DNA copy number alterations in rectal cancer: correlation with metastasis, survival, and mRNA expressionJérôme Doyen, Eric Letouzé, Laetitia Marisa, et al.Hepatology (Baltimore, Md.)|May 15, 2016
Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progressionSandra Rebouissou, Andrea Franconi, Julien Calderaro, et al.Cell Reports|April 3, 2020
TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal TransitionAurélie Morin, Judith Goncalves, Sophie Moog, et al.Journal of Hepatology|May 24, 2017
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classificationJulien Calderaro, Gabrielle Couchy, Sandrine Imbeaud, et al.Cancer Research|April 8, 2022
Structure, Dynamics, and Impact of Replication Stress-Induced Structural Variants in Hepatocellular CarcinomaQuentin Bayard, Pierre Cordier, Camille Péneau, et al.Journal of Hepatology|December 26, 2016
Germline and somatic DICER1 mutations in familial and sporadic liver tumorsStefano Caruso, Julien Calderaro, Eric Letouzé, et al.Nature Cancer|August 31, 2023
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivationJennifer Derrien, Sarah Gastineau, Antoine Frigout, et al.Plos One|January 4, 2013
Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutationsAudrey Rouault, Guillaume Banneau, Gaëtan Macgrogan, et al.Pageof 8